Last checked at 2 Jan 2019 07:00
02 January 2019
Avacta Group plc
("Avacta", the "Group" or the "Company")
Director's Dealing
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, announces that its Chief Financial Officer, Tony Gardiner, has purchased on 31 December 2018 8,196 ordinary shares of 10p each in the Company ("Ordinary Shares") at a price of 30.5 pence per Ordinary Share.
Following this transaction, Tony Gardiner's total beneficial interest in the Company is 8,196 Ordinary Shares, representing less than 0.1% of Avacta's issued share capital. In addition, Tony Gardiner has a joint interest in 150,000 Ordinary Shares; such Ordinary Shares are jointly held by certain Directors individually and Avacta Group Trustee Limited in its capacity as trustee of The Avacta Employees' Share Trust.
- Ends -
For further information from Avacta Group plc, please contact:
Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer
| Tel: +44 (0) 844 414 0452 www.avacta.com |
finnCap Ltd Geoff Nash / Giles Rolls - Nominated Adviser Tim Redfern / Sunila de Silva - ECM
WG Partners Nigel Birks / Nigel Barnes David Wilson / Claes Spang
| Tel: +44 (0) 207 220 0500 www.finncap.com
Tel: +44 (0) 203 705 9318 Tel: +44 (0) 203 705 9217 www.wgpartners.co.uk
|
Turner Pope Investments James Pope / Ben Turner
Zyme Communications (Trade and Regional Media) Katie Odgaard
Yellow Jersey (Financial Media and IR) Sarah Hollins Harriet Jackson | Tel: +44 (0) 203 621 4120www.turnerpope.com
Tel: +44 (0)7787 502 947 www.zymecommunications.com
Tel: +44 (0)7764 947137 Tel: +44 (0)7544 275882 avacta@yellowjerseypr.com |
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer® technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer® technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer® reagents through licensing to developers of life sciences research tools and diagnostics.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Tony Gardiner | ||||
2. | Reason for the Notification | |||||
a) | Position/status | Chief Financial Officer | ||||
b) | Initial notification/Amendment |
| ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Avacta Group Plc | ||||
b) | LEI | 2138009U3EG31OPMGH36 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the Financial instrument, type of instrument |
| ||||
Identification code | GB00BYYW9G87 | |||||
b) | Nature of the transaction |
| ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: · Aggregated volume · Price |
See above | ||||
e) | Date of the transaction | 31 December 2018 | ||||
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||